JP2005514370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005514370A5 JP2005514370A5 JP2003546880A JP2003546880A JP2005514370A5 JP 2005514370 A5 JP2005514370 A5 JP 2005514370A5 JP 2003546880 A JP2003546880 A JP 2003546880A JP 2003546880 A JP2003546880 A JP 2003546880A JP 2005514370 A5 JP2005514370 A5 JP 2005514370A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- carbon atoms
- formula
- branched alkyl
- indole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 83
- 125000000217 alkyl group Chemical group 0.000 claims 71
- 125000000623 heterocyclic group Chemical group 0.000 claims 58
- -1 t-butoxycarbonyl Chemical group 0.000 claims 49
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims 33
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 33
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 33
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 33
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 33
- 229910052760 oxygen Inorganic materials 0.000 claims 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 23
- 125000004429 atom Chemical group 0.000 claims 23
- 150000001875 compounds Chemical class 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 22
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims 21
- 150000003863 ammonium salts Chemical class 0.000 claims 19
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 14
- 229910052783 alkali metal Inorganic materials 0.000 claims 13
- 150000001340 alkali metals Chemical class 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 125000002950 monocyclic group Chemical group 0.000 claims 13
- 206010012289 Dementia Diseases 0.000 claims 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 12
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 12
- 125000005842 heteroatom Chemical group 0.000 claims 12
- 229910052757 nitrogen Inorganic materials 0.000 claims 12
- 239000001301 oxygen Substances 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 12
- 229910052717 sulfur Inorganic materials 0.000 claims 12
- 239000011593 sulfur Substances 0.000 claims 12
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims 11
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 11
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 claims 11
- 241000723346 Cinnamomum camphora Species 0.000 claims 11
- 125000002619 bicyclic group Chemical group 0.000 claims 11
- 229960000846 camphor Drugs 0.000 claims 11
- 229930008380 camphor Natural products 0.000 claims 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims 11
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 claims 11
- 125000005561 phenanthryl group Chemical group 0.000 claims 11
- 125000003831 tetrazolyl group Chemical group 0.000 claims 11
- 208000024827 Alzheimer disease Diseases 0.000 claims 10
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 10
- 150000001342 alkaline earth metals Chemical class 0.000 claims 10
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 10
- 125000003277 amino group Chemical group 0.000 claims 10
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 claims 10
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims 5
- 230000003412 degenerative effect Effects 0.000 claims 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims 3
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims 3
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims 2
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 101001017818 Homo sapiens ATP-dependent translocase ABCB1 Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010044688 Trisomy 21 Diseases 0.000 claims 2
- 210000004102 animal cell Anatomy 0.000 claims 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001054 cortical effect Effects 0.000 claims 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 210000004558 lewy body Anatomy 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 208000037259 Amyloid Plaque Diseases 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 230000006933 amyloid-beta aggregation Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 125000002785 azepinyl group Chemical group 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 150000001555 benzenes Chemical class 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 229920001577 copolymer Chemical compound 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 239000003540 gamma secretase inhibitor Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000002636 imidazolinyl group Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000005956 isoquinolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 230000000508 neurotrophic effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001422 pyrrolinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000005493 quinolyl group Chemical group 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 claims 1
- 230000002739 subcortical effect Effects 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
- 0 O=S(*c1ccccc1)=O Chemical compound O=S(*c1ccccc1)=O 0.000 description 19
- XGGSSQJBGCGUEG-UHFFFAOYSA-N COc1cccc(CCC(N=C)=O)c1 Chemical compound COc1cccc(CCC(N=C)=O)c1 XGGSSQJBGCGUEG-UHFFFAOYSA-N 0.000 description 1
- SNHMUERNLJLMHN-UHFFFAOYSA-N Ic1ccccc1 Chemical compound Ic1ccccc1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 1
- IDCKZBGINKOTOL-UHFFFAOYSA-N O=CCCc1ccc2OCOc2c1 Chemical compound O=CCCc1ccc2OCOc2c1 IDCKZBGINKOTOL-UHFFFAOYSA-N 0.000 description 1
- RNAGDYCPGASVOW-UHFFFAOYSA-N O=N[IH]c1ccccc1 Chemical compound O=N[IH]c1ccccc1 RNAGDYCPGASVOW-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33469201P | 2001-11-21 | 2001-11-21 | |
| PCT/US2002/037360 WO2003045378A1 (en) | 2001-11-21 | 2002-11-21 | Amino acid derivatives useful for the treatment of alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005514370A JP2005514370A (ja) | 2005-05-19 |
| JP2005514370A5 true JP2005514370A5 (https=) | 2006-01-05 |
Family
ID=23308367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003546880A Pending JP2005514370A (ja) | 2001-11-21 | 2002-11-21 | アルツハイマー病の治療に有用なアミノ酸誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20060079550A1 (https=) |
| EP (1) | EP1458378B1 (https=) |
| JP (1) | JP2005514370A (https=) |
| AT (1) | ATE326964T1 (https=) |
| AU (1) | AU2002356991A1 (https=) |
| BR (1) | BR0214359A (https=) |
| CA (1) | CA2477585A1 (https=) |
| DE (1) | DE60211746D1 (https=) |
| MX (1) | MXPA04004903A (https=) |
| WO (1) | WO2003045378A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1289469C (zh) * | 2001-12-20 | 2006-12-13 | 布里斯托尔-迈尔斯斯奎布公司 | α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂 |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| US7230133B2 (en) | 2003-05-01 | 2007-06-12 | Bristol-Myers Squibb Company | Malonamides and malonamide derivatives as modulators of chemokine receptor activity |
| EP1656359B1 (en) * | 2003-08-14 | 2012-11-28 | Merck Sharp & Dohme Corp. | Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease |
| AU2004277981B2 (en) * | 2003-10-03 | 2009-10-01 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease |
| RU2364587C2 (ru) * | 2003-10-29 | 2009-08-20 | Элан Фармасьютикалз, Инк. | N-замещенные бензолсульфонамиды |
| AU2004293416B2 (en) * | 2003-11-24 | 2009-09-24 | Merck & Co., Inc. | Benzylether and benzylamino beta-secretase inhibitors for the treatment of Alzheimer's disease |
| KR20080015079A (ko) | 2005-04-08 | 2008-02-18 | 코멘티스, 인코포레이티드 | 베타 세크레타제 활성을 억제하는 화합물 및 이것의 사용방법 |
| GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
| EP2285774B1 (en) | 2008-06-05 | 2015-02-25 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Novel modulators of protein kinase signaling |
| CN103242200A (zh) * | 2013-04-10 | 2013-08-14 | 吉尔生化（上海）有限公司 | 一种Nα-芴甲氧羰基-Nε-乙酰基-赖氨酸的制备方法 |
| US9770454B2 (en) | 2013-07-14 | 2017-09-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases |
| CN112353938A (zh) | 2015-02-05 | 2021-02-12 | 特尔诺沃有限公司 | 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合 |
| CN109265371A (zh) * | 2018-10-12 | 2019-01-25 | 吉尔生化（上海）有限公司 | 一种Nα-[(9H-芴-9-基甲氧基)羰基]-Nε-乙酰基-L-赖氨酸的制备方法 |
| CN109824547A (zh) * | 2019-03-20 | 2019-05-31 | 康化（上海）新药研发有限公司 | 一种双不同保护氨基酸的合成方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251928B1 (en) * | 1994-03-16 | 2001-06-26 | Eli Lilly And Company | Treatment of alzheimer's disease employing inhibitors of cathepsin D |
| US5986102A (en) * | 1998-04-29 | 1999-11-16 | Pharmacopeia, Inc. | Hydroxypropylamide peptidomimetics as inhibitors of aspartyl proteases |
| CN1300320C (zh) * | 1998-09-24 | 2007-02-14 | 法玛西雅厄普约翰美国公司 | 阿尔茨海默氏疾病分泌酶 |
| US6455587B1 (en) * | 2000-03-15 | 2002-09-24 | Pharmacor Inc. | Amino acid derivatives as HIV aspartyl protease inhibitors |
-
2002
- 2002-11-21 CA CA002477585A patent/CA2477585A1/en not_active Abandoned
- 2002-11-21 WO PCT/US2002/037360 patent/WO2003045378A1/en not_active Ceased
- 2002-11-21 BR BR0214359-3A patent/BR0214359A/pt not_active IP Right Cessation
- 2002-11-21 MX MXPA04004903A patent/MXPA04004903A/es not_active Application Discontinuation
- 2002-11-21 DE DE60211746T patent/DE60211746D1/de not_active Expired - Lifetime
- 2002-11-21 AT AT02804013T patent/ATE326964T1/de not_active IP Right Cessation
- 2002-11-21 JP JP2003546880A patent/JP2005514370A/ja active Pending
- 2002-11-21 US US10/496,242 patent/US20060079550A1/en not_active Abandoned
- 2002-11-21 AU AU2002356991A patent/AU2002356991A1/en not_active Abandoned
- 2002-11-21 EP EP02804013A patent/EP1458378B1/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005514370A5 (https=) | ||
| JPWO2005047286A1 (ja) | スピロ複素環化合物 | |
| EP1438973A1 (en) | Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists | |
| JPWO2005040135A1 (ja) | 抗ストレス薬およびその医薬用途 | |
| CN110305095A (zh) | 色甘酸衍生物以及成像和治疗的相关方法 | |
| RU99115750A (ru) | Новые соединения с анальгезирующим действием | |
| SK287828B6 (sk) | 5-Halo-tryptamine derivatives used as ligands of 5-HT6 and/or 5-HT7 serotonin receptors | |
| JPWO2005063241A1 (ja) | ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および／または治療剤 | |
| JP2006516640A (ja) | 新規アリールピペラジニル化合物 | |
| JP4351909B2 (ja) | 薬剤を調製するための、２−オキソ−１−ピロリジン誘導体の使用 | |
| BRPI0817864A2 (pt) | uso de um composto derivado de ceramida | |
| JP2005508940A5 (https=) | ||
| JP2019502686A5 (https=) | ||
| ES2250345T3 (es) | Derivados sustituidos de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico. | |
| JP2020073513A (ja) | α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| RU2335490C2 (ru) | Соединения карбоновой кислоты, фармацевтическая композиция на их основе, способ лечения и применение | |
| JP5749176B2 (ja) | トリプル再取込み阻害剤及びそれらの使用方法 | |
| KR20070085973A (ko) | 수면 장애 예방 또는 치료제 | |
| CN102202664A (zh) | 包含毒蕈碱性受体拮抗剂和β2肾上腺素受体激动剂的药物产品 | |
| JP2004504377A5 (https=) | ||
| PT1745786E (pt) | Compostos neuroprotetores e composições farmacêuticas que os compreendem | |
| JP5469707B2 (ja) | 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物 | |
| HUP0104533A2 (hu) | Új pirimidinszármazékok és eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények | |
| RU2212237C2 (ru) | Средство для лечения нейрогенного воспаления | |
| CN118678954A (zh) | 作为kv7通道激活剂的吡唑基化合物 |